Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

XOMA Royalty Corporation - Common Stock (NQ:XOMA)

26.66 -1.33 (-4.75%)
Streaming Delayed Price Updated: 1:47 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about XOMA Royalty Corporation - Common Stock

< Previous 1 2 Next >
News headline image
XOMA Royalty Corporation: A Deep Dive into a Biotech Royalty Aggregator (12/13/2025)
XOMA Corporation (Nasdaq: XOMA), operating as XOMA Royalty Corporation since July 2024, has undergone a profound strategic metamorphosis, transitioning from a traditional biopharmaceutical developer to... 
Via PredictStreet
Topics Intellectual Property
News headline image
LAVA Therapeutics Stock Drops After Amended Deal With XOMA Royalty ↗
As per the amended deal, LAVA shareholders will receive an initial cash payment of $1.04 per share, down from the range of $1.16 to $1.24 initially agreed upon. 
Via Stocktwits
News headline image
Turnstone Biologics: A $100 Dream Collides with a $0.34 Reality
October 17, 2025 – In the volatile world of biotechnology, ambitious price targets often fuel investor speculation and market buzz. However, for Turnstone Biologics Corp. (NASDAQ: TSTN), the notion of... 
Via MarketMinute
Topics Intellectual Property Workforce
LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting ↗
Via Stocktwits
Mural Oncology To Be Acquired By Xoma Royalty ↗
Via Stocktwits
News headline image
XOMA Royalty Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
XOMA Revenue Jumps 39% in Fiscal Q2 ↗
Via The Motley Fool
News headline image
Turnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment Slumps ↗
XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock plus one non-transferable contingent value right. 
Via Stocktwits
News headline image
The Analyst Verdict: XOMA Royalty In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
Forecasting The Future: 5 Analyst Projections For XOMA Royalty ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On XOMA Royalty Through 4 Analysts ↗
 
Via Benzinga
News headline image
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q2 2024 ↗
XOMA stock results show that XOMA missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Demystifying XOMA: Insights From 5 Analyst Reviews ↗
 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring XOMA Through Analyst Insights ↗
 
Via Benzinga
News headline image
Cracking The Code: Understanding Analyst Reviews For XOMA ↗
 
Via Benzinga
News headline image
FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base ↗
FDA's Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C on August 2. PDUFA decision expected by September 21. 
Via Benzinga
News headline image
3 Crazy Good Stocks to Buy With $500 Right Now ↗
For investors with only a little money to spare, these three supercharged stocks represent an outrageous opportunity for future growth. 
Via InvestorPlace
News headline image
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024 ↗
XOMA stock results show that XOMA missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023 ↗
XOMA stock results show that XOMA missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Recap: XOMA Q4 Earnings ↗
 
Via Benzinga
News headline image
Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma ↗
XOMA acquires Kinnate Biopharma for $2.3352 per share, with potential additional cash. The acquisition is expected to close in April 2024. 
Via Benzinga
News headline image
XOMA's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
XOMA Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  On Friday, 57 companies reached new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  During Monday, 102 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  During Thursday, 56 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  Wednesday saw 59 companies set new 52-week lows. 
Via Benzinga
News headline image
Arimoclomol and Aldoxorubicin Acquisition to Bolster XOMA's Revenue Growth: Analyst ↗
Earlier today, XOMA Corporation (NASDAQ: XOMA) acquired the royalty and milestone rights associated with two assets from LadRx Corporation: arimoclomol for Niemann-Pick disease type C, and... 
Via Benzinga
News headline image
Recap: XOMA Q1 Earnings ↗
XOMA (NASDAQ:XOMA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:30 AM. Here's what investors need to know about the announcement. Earnings XOMA missed estimated earnings by 96.0%,... 
Via Benzinga
News headline image
XOMA: Q1 Earnings Insights ↗
XOMA (NASDAQ:XOMA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:30 AM. Here's what investors need to know about the announcement. Earnings XOMA missed estimated earnings by 96.0%,... 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.